Upjohn Company Profile

✉ Email this page to a colleague

UPJOHN has thirteen approved drugs.

There are three US patents protecting UPJOHN drugs.

There are thirty-three patent family members on UPJOHN drugs in thirty-three countries and thirty-nine supplementary protection certificates in thirteen countries.

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upjohn	DETROL LA	tolterodine tartrate	CAPSULE, EXTENDED RELEASE;ORAL	021228-002	Dec 22, 2000	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Upjohn	XANAX XR	alprazolam	TABLET, EXTENDED RELEASE;ORAL	021434-004	Jan 17, 2003	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
Upjohn	XANAX XR	alprazolam	TABLET, EXTENDED RELEASE;ORAL	021434-003	Jan 17, 2003	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-001	Dec 30, 2004	AB	RX	Yes	No		⤷ Sign Up				⤷ Sign Up
Upjohn	LYRICA	pregabalin	CAPSULE;ORAL	021446-008	Dec 30, 2004	AB	RX	Yes	Yes		⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-003	Aug 29, 2002	RE44048*PED	⤷ Sign Up
Upjohn	CELEBREX	celecoxib	CAPSULE;ORAL	020998-002	Dec 31, 1998	5,760,068*PED	⤷ Sign Up
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-001	Oct 20, 1997	5,916,923*PED	⤷ Sign Up
Upjohn	LIPITOR	atorvastatin calcium	TABLET;ORAL	020702-004	Apr 7, 2000	RE40667*PED	⤷ Sign Up
Upjohn	EFFEXOR XR	venlafaxine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020699-004	Oct 20, 1997	6,419,958*PED	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Capsules	2 mg and 4 mg	➤ Subscribe	2007-07-30
➤ Subscribe	Capsules	50 mg	➤ Subscribe	2008-03-21
➤ Subscribe	Oral Solution	20 mg/mL	➤ Subscribe	2010-05-19
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Extended-release Tablets	82.5 mg and 165 mg	➤ Subscribe	2018-02-02
➤ Subscribe	Tablets	20 mg and 40 mg	➤ Subscribe	2010-03-29
➤ Subscribe	Extended-release Tablets	37.5 mg, 75 mg and 150 mg	➤ Subscribe	2007-05-03
➤ Subscribe	Capsules	25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg	➤ Subscribe	2008-12-30
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Extended-release Tablets	330 mg	➤ Subscribe	2018-01-29
➤ Subscribe	Tablets	25 mg and 50 mg	➤ Subscribe	2006-09-27

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0641330	C300164	Netherlands	⤷ Sign Up	PRODUCT NAME: PREGABALINE, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/04/279/001 20040706
3461484	301101	Netherlands	⤷ Sign Up	PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108
0731795	10075033	Germany	⤷ Sign Up	PRODUCT NAME: CELECOXIB; NAT. REGISTRATION NO/DATE: 48802.00.00 20000518; FIRST REGISTRATION: SE 14838 19991203
0364417	SPC/GB97/014	United Kingdom	⤷ Sign Up	PRODUCT NAME: LATANOPROST (I.E. 13,14-DIHYDRO-17-PHENYL-18,19,20-TRINOR-PGF-ALPHA-ISOPROPYLESTER); NAT. REGISTRATION NO/DATE: 00032/0220 19961216; FIRST REGISTRATION: SE 12716 19960718; SPC EXTENSION AUTHORISATION: PL00057/1057-008 20101216
1003503	05C0048	France	⤷ Sign Up	PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.